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ABSTRACT: The galectin family of glycan-binding
proteins is thought to mediate many cellular processes
by oligomerizing cell surface glycoproteins and glycolipids
into higher-order aggregates. This hypothesis reﬂects the
known oligomeric states of the galectins themselves and
their binding properties with multivalent ligands in vitro,
but direct evidence of their ability to cross-link ligands on a
cell surface is lacking. A major challenge in fundamental
studies of galectin−ligand interactions is that their natural
ligands comprise a heterogeneous collection of glyco-
conjugates that share related glycan structures but
disparate underlying scaﬀolds. Consequently, there is no
obvious means to selectively monitor the behaviors of
natural galectin ligands on live cell surfaces. Here we
describe an approach for probing the galectin-induced
multimerization of glycoconjugates on cultured cells.
Using RAFT polymerization, we synthesized well-deﬁned
glycopolymers (GPs) functionalized with galectin-binding
glycans along the backbone, a lipid group on one end and
a ﬂuorophore on the other. After insertion into live cell
membranes, the GPs’ ﬂuorescence lifetime and diﬀusion
time were measured in the presence and absence of
galectin-1. We observed direct evidence for galectin-1-
mediated extended cross-linking on the engineered cells, a
phenomenon that was dependent on glycan structure. This
platform oﬀers a new approach to exploring the “galectin
lattice” hypothesis and to deﬁning galectin ligand
speciﬁcity in a physiologically relevant context.
M
any cellular processes are regulated by multimerization
of cell surface proteins and lipids.
1 In many systems,
biomolecules assemble into higher-order clusters through direct
protein−protein interactions. However in some cases, auxiliary
proteins provide scaﬀolding for oligomeric assemblies via
recognition of post-translational modiﬁcations.
2 The galectins, a
family of secreted glycan-binding proteins, are thought to serve
such a function by interacting with speciﬁc glycan structures
covalently bound to cell surface proteins and lipids.
3 Evidence
that both the galectins as well as many of their native ligands
are multivalent has led to the proposal of a “galectin lattice”
model, in which galectins can segregate membrane-associated
glycoproteins and glycolipids into discrete microdomains.
4
Galectin-mediated assemblies have been implicated in the
regulation of cell signaling, adhesion, migration, and prolifer-
ation,
5 and their dysfunctions have been associated with
autoimmune disease
6 and cancer.
7 As well, Dennis and co-
workers have proposed that galectin lattices can regulate the
cell surface half-lives of glycoproteins by retarding their
endocytosis.
8
Despite compelling evidence for the galectins’ role in
modulating the behaviors of cell surface molecules, galectin-
mediated ligand cross-linking has not been directly observed on
live cells. A majority of studies addressing the galectins’ cross-
linking ability have relied on in vitro binding assays.
9 In one cell-
based study, Nieminen et al. demonstrated that galectin-3 exists
in a multivalent state, a requirement for cross-linking, on
neutrophil and endothelial cell surfaces through Förster
resonance energy transfer (FRET) imaging.
10 However, the
eﬀects of galectin binding on ligand multimerization have not
been directly addressed in cell-based systems, a challenge that is
exacerbated by the nature of the galectins’ endogenous ligands:
they comprise a heterogeneous collection of glycoconjugates
that share related glycan structures but disparate underlying
scaﬀolds. There is no straightforward means to selectively label
such a complex ligand mixture with biophysical probes that
would enable studies of their oligomerization. Speciﬁc
glycoproteins, such as integrins,
11 mucins,
12 the T cell
receptor,
6 and EGFR,
8 have been found to bind galectins in
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Figure 1. An experimental platform for probing galectin-mediated
ligand cross-linking on live cell surfaces. Synthetic GPs were adorned
with galectin-binding glycans (blue hexagons) and functionalized with
a lipid on one end and either a FRET donor or acceptor dye on the
other. The GPs were inserted into live cell membranes, and their
ﬂuorescence lifetimes (τFL) and diﬀusion times (τD) were monitored.
The galectin-dependent decrease in τFL and increase in τD provided
evidence of cell-surface GP cross-linking and oligmerization.
Communication
pubs.acs.org/JACS
© 2012 American Chemical Society 9549 dx.doi.org/10.1021/ja301694s | J. Am. Chem. Soc. 2012, 134, 9549−9552biochemical assays. In principle, the inﬂuence of galectins on
these proteins’ cell-surface behavior can be monitored using
GFP fusions and ﬂuorescent antibodies. But on live cells, it is
likely that only a subset of their heterogeneous glycoforms
engage galectins and form oligomers, which complicates
analyses focusing only on the protein component of the ligand.
Synthetic glycopolymers (GPs) have proven to be powerful
functional surrogates for natural glycoconjugates, particularly in
situations where the complexity and heterogeneity of the native
biomolecules undermine experimental inquiry.
13 For decades,
chemists have made use of various GP architectures to study
glycan−receptor interactions related to the immune response,
14
viral infection,
15 and neurobiology,
16 and recently we employed
synthetic GPs as ligands for microarray-based studies of glycan
binding proteins
17 and for cell-surface functionalization.
18
Here we present a new platform for investigating galectin-
mediated cross-linking on live cell surfaces utilizing membrane-
associated GPs as chemically deﬁned ligands (Figure 1). The
GPs were designed to possess the following attributes: (1)
galectin-binding glycans distributed across the polymer back-
bone similarly to galectin-binding mucin glycoproteins,
12 (2) a
lipid anchor at one end, and (3) a FRET donor or acceptor
ﬂuorophore at the other end. The lipid tail enables insertion of
the GP into live cell membranes and control of polymer
orientation at the cell surface.
18 The ﬂuorescent dyes allow
simultaneous monitoring of GP cross-linking by FRET as well
as detection of higher-order assemblies by ﬂuorescence
correlation spectroscopy (FCS). Using this experimental
platform we found direct evidence for the formation of cell-
surface ligand clusters in the presence of galectin-1. More
broadly, the method should facilitate interrogation of the
galectin-lattice model in the physiologically relevant context of
cell surfaces.
Well-deﬁned GPs were synthesized by reversible addition−
fragmentation chain transfer (RAFT) polymerization, which
enables facile dual end-functionalization of the polymer chain.
19
We incorporated the disaccharide lactose or cellobiose into the
polymers using acrylamide monomers 2 and 3, respectively.
Lactose binds a variety of galectins with KD’s in the low
millimolar to high micromolar range
20 and can be used at high
concentrations to inhibit galectin binding to membrane-
associated glycoproteins and glycolipids.
21 Oligomeric forms
of lactose, however, bind multimeric galectins with considerably
higher avidities,
22 a phenomenon that has been shown to
govern natural galectin−ligand interactions as well.
23 Cello-
biose, the C-4′ epimer of lactose, was chosen as a structurally
similar control ligand for our investigations based on its
reported lack of binding to galectin-1, the family member we
studied in this work.
24
We synthesized lipid-functionalized trithiocarbonate 1
(Scheme 1 and Supporting Information) as a chain transfer
a g e n tt h a tw ep r e d i c t e dw o u l dp e r f o r mw e l li nl i v i n g
polymerization of acrylamide monomers 2 and 3 based on
literature precedents.
25 The polymerization was performed in a
mixture of water and N,N-dimethylformamide (Scheme 1) and
yielded GPs 4 and 5 with PDIs of ∼1.2 in high conversion
(>90%). Of note, minimizing the hydrophobicity of the ‘Z’ (i.e.,
ethyl) group of 1 was important for optimal conversion and
PDI. Long alkyl groups at this position, which are commonly
employed in chain transfer agents, resulted in aggregation of
the growing polymer chain during the reaction. The
trithiocarbonate end groups of 4 and 5 were cleaved with
sodium borohydride, and the resulting free sulfhydryl groups
were conjugated with maleimide-functionalized Alexa Fluor 488
(6 and 7) or Alexa Fluor 555 (8 and 9). These ﬂuorescent
lipid-functionalized GPs were used in all subsequent experi-
ments.
We next sought to display polymers 6 and 7 on live cells for
galectin binding studies. Most cell types express endogenous
glycoproteins that possess galectin-binding N-acetyllactosamine
(LacNAc, Galβ1,4GlcNAc) residues.
26 In this initial study, we
tried to minimize the impact of endogenous ligands on
galectin−GP interactions by choosing a cell line that is deﬁcient
in galactosides, the ldlD Chinese Hamster Ovary (CHO) cell
mutant.
27 ldlD CHO cells were incubated with 6 or 7 for 50
min at rt and imaged using ﬂuorescence microscopy to assess
cell surface incorporation. Consistent with previous studies,
18
both GPs produced robust ﬂuorescence localized at the cell
membrane as well as within endocytic vesicles (Figure 2B and
F, and Figures S1, S6, and S7).
For our initial studies we chose galectin-1, a homodimer with
two carbohydrate recognition domains (CRDs) at opposite
poles of its 3-D structure.
28 The distance between the two
Scheme 1. RAFT Polymerization and Functionalization of GPs
Figure 2. Fluorescence microscopy of ldlD CHO cells treated with GP
6 (A−D) or 7 (E−H) followed by ﬂuorescently labeled Galectin-1,
Gal-1-555 (D and G). Hoechst 33342 was used to stain the nuclei (A
and E). Galectin-1 binding was observed on cells incubated with GP 6
(C) but not with GP 7 (G).
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FRET pair Alexa Fluor 488 and 555. To explore galectin-1’s
ability to bind GPs 6 and 7 when displayed on live cells,
galectin-1 was ﬂuorescently labeled with Alexa Fluor 555
(generating Gal-1-555) as previously described.
29 ldlD CHO
cells previously treated with either 6 or 7 were incubated with
labeled galectin-1, imaged using ﬂuorescence microscopy or
analyzed by ﬂow cytometry.
Cells displaying lactosyl GP 6 showed signiﬁcant Gal-1-555
binding (Figure 2C), whereas cells displaying cellobiosyl GP 7
did not (Figure 2G), mirroring the known monomeric ligand
preference of galectin-1. Flow cytometry analysis of cells treated
similarly gave comparable results (Figure S2), although a low
amount of Gal-1-555 binding to cell-associated GP 7 was
observed. It is likely that galectin-1’s interaction with cellobiose,
though too weak to detect at the monomer level, becomes
discernible with multivalent polymers. Overall, these results
show that cells deﬁcient in endogenous ligands can be
engineered using synthetic GPs to bind galectin-1.
The impact of galectin-1 binding on the oligomerization state
and mobility of bound GPs was assessed using ﬂuorescence
lifetime measurements by time-correlated single-photon
counting (TCSPC) and FCS. The principle of the experiment
is as follows. GPs 6 and 8 possess identical backbone and
glycan structures but disparate dyes that constitute a FRET
pair. The GP pair can be codisplayed on cell membranes in a
1:1 ratio. In the ns regime, ﬂuorescence lifetime measurements
can probe for galectin-1-mediated cross-linking since the
depletion of excited states of donor 6 by proximal acceptor 8
(d < Ro) decreases the overall ﬂuorescence lifetime (τFL)o f6.
30
Further, FCS operates by performing an autocorrelation
analysis on the ﬂuorescence ﬂuctuations in an ∼1 fL excitation
volume over many time scales, ns to s.
31 Ad i ﬀusion time (τD)
parameter can be extracted from the autocorrelation function,
ultimately quantifying the relative mobility of the GPs on the
cell surface. The formation of GP clusters would be implied by
observed increases in diﬀusion time.
ldlD CHO cells were ﬁrst incubated with GPs 6 and 8 (1:1
ratio), and the time-resolved ﬂuorescence intensity of donor 6
was monitored on single live cells with a ps laser pulse at 10
MHz in the presence or absence of unlabeled galectin-1.
32
Fluorescence lifetime and diﬀusion time were calculated at 10-
min intervals. In the absence of galectin-1, donor 6’s
ﬂuorescence lifetime increased with time (Figure 3A). We
attribute this phenomenon to endocytosis of the GPs, as
evident in our microscopy images. As a consequence, the GPs’
density on the cell surface decreases over time, which would
reduce the background level of FRET among unclustered GP
molecules. Indeed, at lower temperatures at which endocytosis
is slower (11−13 °C), the ﬂuorescence lifetime of donor 6
increased at a slower rate (Figure S3).
Next, we monitored the ﬂuorescence lifetime of donor 6 after
adding galectin-1 to cells labeled with 6 and 8. We observed a
marked decrease in ﬂuorescence lifetime of donor 6 over a
period of 40 min (Figure 3A). We repeated the experiment on
six diﬀerent cells and observed similar results; the average
changes in ﬂuorescence lifetime are shown in Figure 3B. These
observations suggest that cross-linking of donor 6 and acceptor
8 by galectin-1 enhanced FRET and, consequently, decreased
the ﬂuorescence lifetime of donor 6. We performed a
comparable experiment using the cellobiosyl GP FRET pair 7
and 9. Despite the presence of galectin-1, the ﬂuorescence
lifetime of donor 7 increased with time, consistent with
endocytosis and little cross-linking. The observed increase was
not as dramatic as that observed in the absence of galectin-1,
probably reﬂecting GP 7’s weak interaction with the protein as
previously observed by ﬂow cytometry (Figure S2). Impor-
tantly, the galectin-1-dependent decrease in ﬂuorescence
lifetime of GP 6 was entirely inhibitable by soluble lactose
(200 mM) (Figure 3B). In the presence of this galectin-1
competitor, no signiﬁcant galectin-1-mediated cross-linking was
observed. Additional evidence for a direct interaction between
galectin-1 and donor 6 was demonstrated through a FRET
experiment with ﬂuorescently labeled galectin-1 (Figure S3).
Using the same data acquired for ﬂuorescence lifetime
measurements, diﬀusion times were calculated for donor 6 over
the 40-min time course in the presence or absence of galectin-1.
Examples of autocorrelation functions (A and B) and diﬀusion
time values (C) are shown in Figure 4. In the absence of
galectin-1, diﬀusion times for donor 6 were relatively stable
(Figure 4C), indicating that the mobility of 6 on living cells
does not change signiﬁcantly over time. Notably, the diﬀusion
time for donor 6 noticeably increased over time after addition
Figure 3. Fluorescence lifetime measurements of GPs on ldlD CHO
cells. (A) Fluorescence lifetime, Δτ(t), measurements of donor 6 in
the absence (dotted) or presence (solid) of galectin-1 as a function of
time. Δτ(t) represents the diﬀerence between τ(t) and τ(0). Error bars
indicate the standard deviation. (B) The diﬀerence in ﬂuorescence
lifetime (Δτ) between t = 20 and t = 0 min, averaged over six diﬀerent
cells. *P < 0.01; **P < 0.005. Gal-1: unlabeled galectin-1; Lac: 200
mM lactose. Error bars indicate the standard error.
Figure 4. FCS of GP 6 on ldlD CHO cells. Autocorrelation curves for
donor 6 in the absence (A) or presence (B) of galectin-1 at 0 min
(blue) and 20 min (green). (C) Diﬀusion time, τD, for donor 6 in the
absence (dotted) or presence (solid) of galectin-1. (D) The diﬀerence
in diﬀusion time (ΔτD) of donor 6 at t = 20 and 0 min averaged over
six diﬀerent cells. *P < 0.05. Gal-1: unlabeled galectin-1; Lac: 200 mM
lactose. Error bars indicate the standard error.
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donor 6’s mobility provides evidence for oligomerization on the
cell surface. As before, we averaged the diﬀusion time values
from six diﬀerent cells and calculated the diﬀerence between
those values at t = 20 and 0 min (Figure 4D). The data conﬁrm
that galectin-1 increased the diﬀusion time of donor 6, which is
indicative of reduced mobility and oligomerization of the GP.
Free lactose abrogated galectin-1’si n ﬂuence on mobility,
consistent with a glycan-binding mechanism of oligomerization.
In the presence of 200 mM lactose, the change in diﬀusion time
mirrored that of donor 6 in the absence of galectin-1.
In conclusion, we have established a new methodology for
investigating galectin−glycan interactions on live cell mem-
branes using ﬂuorescently labeled GPs in conjunction with
FRET and FCS. To our knowledge, we have also provided the
ﬁrst experimental evidence for galectin-1-mediated cross-linking
from the perspective of the bound ligand. Studies are underway
addressing the ability of diﬀerent members of the galectin
family to induce such cross-linking. The information should
shed light on the dimensions and dynamics of putative galectin
lattices on the cell surface as well as the eﬀects of the glycan
structure and presentation on galectin recognition and cross-
linking. This approach could ultimately provide insight into
how the various galectin members exert diﬀerent signaling and
organizational functions through cell surface interactions.
Beyond galectin biology, we envision applications in the
study of glycan−receptor interactions between two cells,
wherein changes in oligomerization of receptor-bound GPs
might reveal the preferred cluster size of the associated glycan-
binding protein. As well, the platform can be extended to cell-
surface interactions not involving glycans, as the polymers are
wholly synthetic and can be adorned with any ligand type.
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